Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Majid Mirsadraei (Mashhad, Islamic Republic of Iran), Majid Mirsadraee, Sara Khashkhashi Moghaddam, Parisa Saeidi
Related content which might interest you:
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Efficacy of the Plasma Cluster® device in mild to moderate asthmatic children: A randomized, double-blind, placebo-controlled, proof-of-concept trial Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
Chinese herbs in treatment of postinfectious cough: A multi-centre, randomized, double-blind, placebo-controlled trial Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
A double blind randomised placebo controlled trial of the PPAR-gamma agonist pioglitazone in mild asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial Source: Annual Congress 2010 - COPD exacerbation Year: 2010
Preventive effect of carbocysteine on exacerbation of asthma, GAIA randomised, placebo-controlled multi-centre study Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007
Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Effect of reflexology, homeopathy, and traditional medical treatment in asthma: A randomised, controlled, parallel-group trial Source: Annual Congress 2010 - Questionnaires use and psychological aspects in asthma Year: 2010
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013